title: Mutant IDH1: An immunotherapeutic target in tumors.
abstract: The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4+antitumor T cell response in patients and a syngeneic tumor model in MHC-humanized mice.
authors.affiliation: DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center ; Heidelberg, Germany ; Department of Neurooncology; University Hospital Heidelberg ; Heidelberg, Germany.
authors.forename: Theresa
authors.initials: T
authors.lastname: Schumacher
authors.affiliation: DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center ; Heidelberg, Germany ; Department of Neurooncology; University Hospital Heidelberg ; Heidelberg, Germany.
authors.forename: Lukas
authors.initials: L
authors.lastname: Bunse
authors.affiliation: DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center ; Heidelberg, Germany ; DKTK Clinical Cooperation Unit Neurooncology; German Cancer Research Center ; Heidelberg, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wick
authors.affiliation: DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center ; Heidelberg, Germany ; Department of Neurooncology; University Hospital Heidelberg ; Heidelberg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Platten
keywords: IDH1 mutation; MHC class II epitope; MHC-humanized mice; cancer immunotherapy; glioma; mutation-specific CD4+ T-cells